NASDAQ$TELA

TELA Bio Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

Reported sequential growth driven by increased sales momentum and improving macroeconomic conditions.

TELA Bio reported a 39% increase in revenue to $14.5 million for the second quarter of 2023 compared to the same period in 2022. Gross profit increased to $10.2 million, or 70% of revenue, and the company's cash and cash equivalents totaled $65.3 million following a public offering.

  • Revenue increased by 39% compared to the same period in 2022, reaching $14.5 million.
  • Gross profit was $10.2 million, representing 70% of revenue, compared to 63% in the same period last year.
  • Operating expenses increased to $20.6 million due to higher compensation, travel, consulting fees, and study costs.
  • Cash and cash equivalents totaled $65.3 million following a public offering.

Headline financials

Total Revenue

$14.5M

Previous: $10.4M+39.3%
EPS (adj)

-$0.46

Previous: -$0.88+47.7%
Capital Expenditures

-$272K

Previous: -$536K+49.3%
Free Cash Flow

-$11.1M

Previous: -$13.3M+16.7%
Net Income

-$10.8M

Previous: -$12.7M+15.3%
Operating Income

-$10.4M

Previous: -$10.2M-1.2%
Gross Profit

$10.2M

Previous: $6.55M+55.7%
Cash & Equivalents

$65.3M

Previous: $27.7M+135.4%
Total Assets

$94.4M

Previous: $51.3M+83.9%
Stock-Based Comp

$1.29M

Previous: $1.02M+26.6%

Revenue & EPS history

TELA Bio · Revenue · Quarterly

$14.5M

Q2 2023+39.3%vs Q2 2022
Beat estimate in 8 of 14 quarters(57%)
ActualEstimate

Forward guidance

The company continues to expect full year 2023 revenue to range from $60.0 million to $65.0 million, reflecting growth of 45% to 57% over full year 2022.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

-2.5%

Avg return

Earnings day

-3.0%

Avg return

5 days after

+3.5%

Avg return

30 days after

42%

11 / 26 earnings

Positive

+20.2%

Q1 2024

Best reaction

-37.2%

Q4 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+1.7%-9.3%
Q1 2026-5.3%-18.6%-15.7%
Q3 2025-9.3%-2.7%+3.6%
Q1 2025+7.2%-0.1%+90.7%
Q4 2024-37.2%-44.9%-59.1%
Q3 2024+2.0%+3.0%-1.7%
Q2 2024-23.9%-23.4%-35.0%
Q1 2024+20.2%+21.2%+16.7%
Q4 2023+4.0%+0.9%-13.8%
Q3 2023-20.3%-21.7%-4.5%
Q2 2023-4.8%-1.2%-2.8%
Q1 2023-3.6%-4.8%+11.2%
Q4 2022-5.5%-3.7%-11.3%
Q3 2022+13.8%+11.2%+44.7%
Q2 2022-6.5%+5.5%+0.9%
Q1 2022-5.7%-7.0%-31.4%
Q4 2021-4.8%-4.8%-20.4%
Q3 2021-3.8%-3.7%-1.7%
Q2 2021+5.0%+4.4%-8.3%
Q1 2021+3.2%+11.5%+5.9%
Q4 2020-6.6%+0.9%-1.8%
Q3 2020-3.5%-0.8%-3.6%
Q2 2020+5.4%+4.1%+20.7%
Q1 2020-2.4%-3.6%+38.6%
Q4 2019+0.6%-0.4%+34.0%
Q3 2019+13.9%+8.8%+32.6%
Q2 2019
Q1 2019
Q4 2018
Q3 2018
Q2 2018
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro